Table 1. Clinicopathologic characteristics according to expression level of KRAS mRNA in TCGA and METABRIC databases.
| Group | TCGA (RNA seq, median value) | METABRIC (RNA mic, median value) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subgroup | Low | High | Sum | p* | Subgroup | Low | High | Sum | p* | |
| All | 657 (60.1) | 436 (39.9) | 1,093 (100.0) | 1,026 (53.9) | 878 (46.1) | 1,904 (100.0) | ||||
| Age (yr) | ≤ 50 | 198 (30.1) | 131 (30.0) | 329 (30.1) | 0.717 | ≤ 50 | 236 (23.0) | 199 (22.7) | 435 (22.8) | 0.861 |
| > 50 | 458 (69.7) | 305 (70.0) | 763 (69.8) | > 50 | 790 (77.0) | 679 (77.3) | 1,469 (77.2) | |||
| Unknown | 1 (0.2) | 0 (0.0) | 1 (0.1) | Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| T category | 1 | 172 (26.2) | 107 (24.5) | 279 (25.5) | 0.198 | ≤ 2 cm | 459 (44.7) | 362 (41.2) | 821 (43.1) | 0.172 |
| 2 | 379 (57.7) | 254 (58.3) | 633 (57.9) | > 2 cm | 553 (53.9) | 508 (57.9) | 1,061 (55.7) | |||
| 3 | 87 (13.2) | 51 (11.7) | 138 (12.6) | Unknown | 14 (1.4) | 8 (0.9) | 22 (1.2) | |||
| 4 | 17 (2.6) | 23 (5.3) | 40 (3.7) | |||||||
| Unknown | 2 (0.3) | 1 (0.2) | 3 (0.3) | |||||||
| N category | 0 | 317 (48.2) | 198 (45.4) | 515 (47.1) | 0.791 | 0 | 537 (52.3) | 446 (50.8) | 983 (51.6) | 0.714 |
| 1 | 215 (32.7) | 146 (33.5) | 361 (33.0) | 1 | 321 (31.3) | 282 (32.1) | 603 (31.7) | |||
| 2 | 67 (10.2) | 53 (12.2) | 120 (11.0) | 2 | 113 (11.0) | 107 (12.2) | 220 (11.6) | |||
| 3 | 45 (6.8) | 32 (7.3) | 77 (7.0) | 3 | 46 (4.5) | 39 (4.4) | 85 (4.5) | |||
| Unknown | 13 (2.0) | 7 (1.6) | 20 (1.8) | Unknown | 9 (0.9) | 4 (0.5) | 13 (0.7) | |||
| M category | 0 | 529 (80.5) | 380 (87.2) | 909 (83.2) | 0.005 | 0 | 764 (74.5) | 630 (71.8) | 1,394 (73.2) | 0.086 |
| 1 | 12 (1.8) | 10 (2.3) | 22 (2.0) | 1 | 2 (0.2) | 7 (0.8) | 9 (0.5) | |||
| Unknown | 116 (17.7) | 46 (10.6) | 162 (14.8) | Unknown | 260 (25.3) | 241 (27.4) | 501 (26.3) | |||
| Anatomic stage group | 1 | 113 (17.2) | 68 (15.6) | 181 (16.6) | 0.569 | 1 | 264 (25.7) | 211 (24.0) | 475 (24.9) | 0.203 |
| 2 | 380 (57.8) | 242 (55.5) | 622 (56.9) | 2 | 440 (42.9) | 360 (41.0) | 800 (42.0) | |||
| 3 | 144 (21.9) | 107 (24.5) | 251 (23.0) | 3 | 58 (5.7) | 57 (6.5) | 115 (6.0) | |||
| 4 | 12 (1.8) | 10 (2.3) | 22 (2.0) | 4 | 2 (0.2) | 7 (0.8) | 9 (0.5) | |||
| Unknown | 8 (1.2) | 9 (2.1) | 17 (1.6) | Unknown | 262 (25.5) | 243 (27.7) | 505 (26.5) | |||
| Estrogen receptor | Negative | 136 (20.7) | 101 (23.2) | 237 (21.7) | 0.371 | Negative | 205 (20.0) | 240 (27.3) | 445 (23.4) | < 0.001 |
| Positive | 494 (75.2) | 312 (71.6) | 806 (73.7) | Positive | 821 (80.0) | 638 (72.7) | 1,459 (76.6) | |||
| Unknown | 27 (4.1) | 23 (5.3) | 50 (4.6) | Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Progesterone receptor | Negative | 207 (31.5) | 135 (31.0) | 342 (31.3) | 0.289 | Negative | 452 (44.1) | 443 (50.5) | 895 (47.0) | 0.005 |
| Positive | 422 (64.2) | 276 (63.3) | 698 (63.9) | Positive | 574 (55.9) | 435 (49.5) | 1,009 (53.0) | |||
| Unknown | 28 (4.3) | 25 (5.7) | 53 (4.8) | Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| HER2 | Negative | 465 (70.8) | 311 (71.3) | 776 (71.0) | 0.289 | Negative | 926 (90.3) | 742 (84.5) | 1,668 (87.6) | < 0.001 |
| Positive | 98 (14.9) | 75 (17.2) | 173 (15.8) | Positive | 100 (9.7) | 136 (15.5) | 236 (12.4) | |||
| Unknown | 94 (14.3) | 50 (11.5) | 144 (13.2) | Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Subtype | HRc+HER2− | 375 (57.1) | 237 (54.4) | 612 (56.0) | 0.387 | Luminal A | 397 (38.7) | 282 (32.1) | 679 (35.7) | < 0.001 |
| HRc+HER2+ | 77 (11.7) | 59 (13.5) | 136 (12.4) | Luminal B | 204 (19.9) | 257 (29.3) | 461 (24.2) | |||
| HRc−HER2+ | 21 (3.2) | 15 (3.4) | 36 (3.3) | HER2 | 106 (10.3) | 114 (13.0) | 220 (11.6) | |||
| HRc−HER2− | 89 (13.5) | 73 (16.7) | 162 (14.8) | Basal | 93 (9.1) | 106 (12.1) | 199 (10.5) | |||
| Unknown | 95 (14.5) | 52 (11.9) | 147 (13.4) | Others and unknown | 226 (22.0) | 119 (13.6) | 345 (18.1) | |||
Values are presented as number of patients (%).
TCGA = The Cancer Genome Atlas; METABRIC = Molecular Taxonomy of Breast Cancer International Consortium; HER2, human epidermal growth factor receptor 2; HRc, hormone receptor, RNA mic, RNA microarray; RNA seq, RNA sequencing.
*χ2 test was used.